It has been uncovered that compared with conventional CD19 CAR-T cells, the combination of IL7 and CCL19 can promote the infiltration, accumulation, and survival of CAR-T cells in lymphoma tissues, further enhancing the antitumor effect of conventional CAR-T cells (54). Here, CCL19 is linked to lymphoma.